-+ 0.00%
-+ 0.00%
-+ 0.00%
AIM ImmunoTech CEO Highlights Biodefense and Military Force Protection in Newly Published ‘Breaking Defense’ Article
Share
Listen to the news

Article by CEO Thomas K. Equels calls for proactive evaluation of broad-spectrum antiviral countermeasures before novel viral threats emerge

Highlights Company’s investigational drug Ampligen® (rintatolimod) and its potential application as a broad-spectrum prophylactic or early-onset antiviral countermeasure in Ebola and its variants

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending